Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flucelvax versus Fluad in healthy adults for breadth of influenza immune response
ACTRN12626000334303Phase 4Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Fluzone Trivalent in influenza (2 arms), sponsored by University of Melbourne. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12626000334303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000334303.